Eric Sullivan
Director/Miembro de la Junta en CHIMERIC THERAPEUTICS LIMITED .
Fortuna: - $ al 31/05/2024
Cargos activos de Eric Sullivan
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CHIMERIC THERAPEUTICS LIMITED | Director/Miembro de la Junta | 30/08/2023 | - |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Director Financiero/CFO | 01/09/2023 | - |
Historial de carrera de Eric Sullivan
Antiguos cargos conocidos de Eric Sullivan.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
BLUEBIRD BIO, INC. | Comptroller/Controller/Auditor | 01/03/2016 | 04/08/2017 |
Treasurer | 01/03/2016 | 04/08/2017 | |
GEMI THER | Corporate Officer/Principal | - | - |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Director de Operaciones | - | - |
Director Financiero/CFO | - | - | |
Presidente | - | - | |
TCR2 THERAPEUTICS INC. | Director Financiero/CFO | 27/06/2022 | - |
Formación de Eric Sullivan.
Bentley University | Undergraduate Degree |
Estadísticas
Internacional
Estados Unidos | 7 |
Australia | 2 |
Operativa
Director of Finance/CFO | 3 |
Comptroller/Controller/Auditor | 1 |
Treasurer | 1 |
Sectorial
Health Technology | 6 |
Consumer Services | 2 |
Health Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
BLUEBIRD BIO, INC. | Health Technology |
CHIMERIC THERAPEUTICS LIMITED | Health Technology |
Empresas privadas | 4 |
---|---|
TCR2 Therapeutics, Inc.
TCR2 Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Triplet Therapeutics, Inc.
Triplet Therapeutics, Inc. Medical/Nursing ServicesHealth Services Triplet Therapeutics, Inc. develops therapy for huntington's , myotonic dystrophy, spin cerebellar ataxias and repeated expansion diseases. The company was founded by Jean-François Formela and Nessan Bermingham is headquartered in Cambridge, MA. | Health Services |
Gemini Therapeutics, Inc.
Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Convergent Therapeutics, Inc.
Convergent Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Convergent Therapeutics, Inc. is a clinical stage pharmaceutical company located in Cambridge, MA. The company focuses on developing next generation radiopharmaceutical therapies for prostate and other cancers. The company's proprietary technology involves dual-targeted radionuclide therapy (RNT) developed by Dr. Neil Bander, a professor of urologic oncology at Weill Cornell Medicine and licensed to Convergent by Cornell University. The company's lead product candidate, Conv01-?, is a monoclonal antibody conjugated with actinium-225 (225Ac), a radioactive alpha particle emitter, designed to bind to the prostate-specific membrane antigen (PSMA). If FDA-approved, Conv01-? would be the first antibody approved to direct a radioisotope to prostate cancer, and the first drug approved for the use of 225Ac in a cancer treatment. The company was founded by Philip Wayne Kantoff and Neil H. Bander, and Philip Wayne Kantoff has been the CEO since incorporation. | Health Technology |
- Bolsa de valores
- Insiders
- Eric Sullivan
- Experiencia